CN Healthy FY2025 10-K/A: $8.4M Net Income, But Notes in Default and Controls Ineffective
UCFI sits 62% above its 52-week low of $3.41 on elevated volume (26× avg).
Summary
Amendment No. 2 to CN Healthy's FY2025 10-K adds only XBRL tagging, but the audited annual report shows $8.4M net income on $27.8M revenue alongside three defaulted promissory notes and ineffective internal controls.
Key Events · Corporate Governance and Compliance · UCFI
-
FY2025 Revenue and Profit Roughly Double
Revenue rose to $27,759,850 from $11,346,907 (+144.6%) and net income to $8,412,519 from $3,996,003 (+110.5%), or $0.17 vs $0.08 per share.
-
Three Promissory Notes in Default
$2,018,500 owed to the underwriter, $1,000,000 to lender Yanjun Jiao and $454,690 to the sponsor have all matured and remain unpaid; the company is negotiating extensions and says its $33,013,749 cash balance covers them.
-
Internal Controls Deemed Ineffective
Management concluded ICFR and disclosure controls were ineffective at December 31, 2025 due to insufficient U.S. GAAP personnel, no oversight committees and inadequate segregation of duties; no auditor attestation is required as an emerging growth company.
-
Trading Halt and CSRC Filing Still Unresolved
The Nasdaq halt in place since October 1, 2025 remains in effect and the company has still not received the CSRC filing notice for its U.S. listing.
Analysis · UCFI · Manufacturing
Filed solely to add the required inline XBRL tagging, Amendment No. 2 to the FY2025 annual report contains no surprise in the numbers themselves. What the audited annual report does put on the record matters: FY2025 revenue of $27.8M and net income of $8.4M, against $33.0M of cash, but also three matured promissory notes in default ($2.02M to the underwriter, $1.0M to a lender, $0.45M to the sponsor), management's conclusion that internal control over financial reporting was ineffective, no insider trading policy in place, and a CSRC filing notice still not received. The company says its cash covers the notes, yet the default status and control weaknesses sit alongside a trading halt that has kept the stock suspended since October 1, 2025.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, UCFI was trading at $5.51 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $287.8M. The 52-week trading range was $3.41 to $14.71. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.